(S)-4′-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes

References

• Bargar E. M., Walle U. K., Bai S. A., Walle T. Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques. Drug Metabolism and Disposition 1983; 11: 266–272
   PubMed Web of Science ®Google Scholar
• Barrett A. M., Cullum V. A. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. British Journal of Pharmacology 1968; 34: 43–55
   PubMed Web of Science ®Google Scholar
• Bichara N., Ching M. S., Blake C. L., Ghabrial H., Smallwood R. A. Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6—studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions. Drug Metabolism and Disposition 1996; 24: 112–118
   PubMed Web of Science ®Google Scholar
• Colangelo P. M., Blouin R. A., Steinmetz J. E., McNamara P. J., DeMaria A. N., Wedlund P. J. Age and propranolol stereoselective disposition in humans. Clinical Pharmacology and Therapeutics 1992; 51: 489–494
   PubMed Web of Science ®Google Scholar
• Colangelo P. M., Blouin R. A., Steinmetz J. E., McNamara P. J., DeMaria A. N., Wedlund P. J. Age and propranolol stereoselective disposition in humans. Clinical Pharmacology and Therapeutics 1992; 51: 489–494
   PubMed Web of Science ®Google Scholar
• Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clinical Pharmacology and Therapeutics 1973; 14: 487–493
   PubMed Web of Science ®Google Scholar
• Ghabrial H., Nand R., Stead C. K., Smallwood R. A., Morgan D. J. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. Journal of Pharmaceutical Sciences 1994; 83: 931–936
   Google Scholar
• Ishida R., Suzuki K., Masubuchi Y., Narimatsu S., Fujita S., Suzuki T. Enzymatic basis for the non-linearity of hepatic elimination of propranolol in the isolated perfused rat liver. Biochemical Pharmacology 1992; 44: 2281–2288
   Google Scholar
• Jones D. B., Mihaly G. W., Smallwood R. A., Webster L. K., Morgan D. J., Madsen N. P. Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the isolated perfused rat liver. Hepatology 1984; 4: 461–466
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Mackichan J. J., Pyszczynski D. R., Jusko W. J. Dose-dependent disposition of oral propranolol in normal subjects. Biopharmaceutics and Drug Disposition 1980; 1: 159–166
   Google Scholar
• Masubuchi Y., Suzuki K., Fujita S., Suzuki T. A possible mechanism of the impairment of hepatic microsomal monooxygenase activities after multiple administration of propranolol in rats. Biochemical Pharmacology 1992; 43: 757–762
   Google Scholar
• Masubuchi Y., Yamamoto L. A., Uesaka M., Fujita S., Narimatsu S., Suzuki T. Substrate stereoeselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes. Biochemical Pharmacology 1993; 46: 1759–1765
   Google Scholar
• Nelson W. L., Bartels M. J. N-dealkylation of propranolol in rat, dog, and man—chemical and stereochemical aspects. Drug Metabolism and Disposition 1984; 12: 345–352
   PubMed Web of Science ®Google Scholar
• Oatis J. J., Russell M. P., Knapp D. R., Walle T. Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. Journal of Medicinal Chemistry 1981; 24: 309–314
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes 1. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Purves R. D. User's Guide to Minim 1.6. Department of Pharmacology, Medical School, University of Otago, DunedinNew Zealand 1989
   Google Scholar
• Ring J. A., Ghabrial H., Ching M. S., Shulkes A., Smallwood R. A., Morgan D. J. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver. Drug Metabolism and Disposition 1995; 23: 190–196
   Google Scholar
• Schenkman J. B., Cinti D. L. Preparation of microsomes with calcium. Methods in Enzymology, Biomembranes, Part C, 52. Academic Press, New York 1978; 83–89
   Google Scholar
• Schneck D. W., Pritchard J. F. The inhibition effect of propranolol pretreatment on its own metabolism in the rat. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 575–581
   PubMed Web of Science ®Google Scholar
• Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 1972; 7: 159–168
   PubMed Web of Science ®Google Scholar
• Silber B. M., Holford N. H., Riegelman S. Dose-dependent elimination of propranolol and its major metabolites in humans. Journal of Pharmaceutical Sciences 1983; 72: 725–732
   PubMed Web of Science ®Google Scholar
• Straka R. J., Lalonde R. L., Pieper J. A., Bottorff M. B., Mirvis D. M. Nonlinear pharmacokinetics of unbound propranolol after oral administration. Journal of Pharmaceutical Sciences 1987; 76: 521–524
   Google Scholar
• Takahashi H., Ogat H., Kanno S., Takeuchi H. Plasma protein binding of propranolol enantiomers as a major determinant of their stereoselective tissue distribution in rats. Journal of Pharmacology and Experimental Therapeutics 1990; 252: 272–278
   PubMed Web of Science ®Google Scholar
• Wagner J. G. Modeling first-pass metabolism. Mathematical and Statistical Approach to Metabolism and Distribution of Chemicals and Drugs, A. Pecile, A. Rescigno. Plenum Press, New York 1988; 129–149
   Google Scholar
• Walle T., Gaffney T. E. Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. Journal of Pharmacology and Experimental Therapeutics 1972; 182: 83–92
   PubMed Web of Science ®Google Scholar
• Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clinical Pharmacology and Therapeutics 1979; 26: 686–695
   PubMed Web of Science ®Google Scholar
• Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clinical Pharmacology and Therapeutics 1980; 27: 22–31
   PubMed Web of Science ®Google Scholar
• Walle T., Walle U. K., Olanoff L. S. Quantitative account of propranolol metabolism in urine of normal man. Drug Metabolism and Disposition 1985; 13: 204–209
   PubMed Web of Science ®Google Scholar
• Wood A. J., Carr K., Vestal R. E., Belcher S., Wilkinson G. R., Shand D. G. Direct measurement of propranolol bioavailability during accumulation to steady-state. British Journal of Clinical Pharmacology 1978; 6: 345–350
   PubMed Web of Science ®Google Scholar